-
公开(公告)号：EP1358886A4
公开(公告)日：2005-08-17
申请号：EP01998170
申请日：2001-11-27
发明人： SUZUKI KAZUO , NAKAJIMA SHIGEKAZU , YANO SHINJI
IPC分类号： A61K31/785 , A61K31/787 , A61P39/02
CPC分类号： A61K31/787 , A61K31/785
摘要： A novel excretion accelerator for accumulative chlorine compounds which is effective in efficiently discharging residual chlorine compounds, typically dioxins, which have come into the body. The excretion accelerator contains a pharmaceutically acceptable anion-exchange resin.
-
公开(公告)号：EP1348442A4
公开(公告)日：2005-02-02
申请号：EP01972719
申请日：2001-10-09
发明人： SUZUKI K , NAKAJIMA S , YANO SHINJI
IPC分类号： A23L1/29 , A23L1/30 , A61K31/785 , A61K31/787 , A61P3/04 , A61K45/00
CPC分类号： A61K31/785 , A23L33/10 , A23L33/30 , A61K31/787 , Y10S514/909 , Y10S514/911
摘要： Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract, an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified by pharmaceutically acceptable anion exchange resins. In particular, antiobestic agents and health foods characterized by lowering body weight and/or visceral fat content without reducing food intake.
-
53.发明公开
公开(公告)号：EP1419772A4
公开(公告)日：2004-11-24
申请号：EP02705169
申请日：2002-03-14
发明人： YAMAZAKI S
IPC分类号： A61K31/439 , A61P1/00 , A61P1/10 , C07D495/04
CPC分类号： C07D495/04 , A61K31/439
摘要： A novel preventive and/or remedy for constipation predominant IBS which contains as the active ingredient a thieno[3,2-b]pyridinecarboxamide derivative represented by the formula (I): (I) (wherein R1 and R2 each independently represents hydrogen or lower alkyl and A represents a substituent selected from the group consisting of 1-azabicyclo[3.2.2]nonyl, 1-azabicyclo[2.2.2]octyl, and the N-oxides of these), a pharmaceutically acceptable salt of the derivative, or a solvate or hydrate of any of these.
-
54.发明公开PROCESS FOR PRODUCING PROTEIN WITH REDUCTION OF ACIDIC SUGAR CHAIN AND GLYCOPROTEIN PRODUCED THEREBY 有权在还原的糖链，并由此产生的糖蛋白用于生产蛋白质的方法
公开(公告)号：EP1283265A4
公开(公告)日：2004-10-20
申请号：EP01930179
申请日：2001-05-16
发明人： MIURA MASAMI , HIROSE MASAAKI , MIWA TAEKO , IRIE HIROYUKI , KUWAE SHINOBU , MIYANO KENMI , OTANI WATARU , OHI HIDEYUKI
CPC分类号： C12N9/1205 , C12P21/005
摘要： It is intended to find out a gene participating in the addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. It is also intended to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene encoding this protein; a variant of this gene; a vector carrying the variant gene; a yeast belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
摘要翻译： 本发明的意图，找出一个基因参与加成磷酸甘露糖的一种糖蛋白的起源的糖链在属于毕赤酵母属的酵母，并且提供控制该的手段。 因此，本发明意图用于生产蛋白质与还原通过使用属于毕赤酵母属如此控制的酵母菌株的酸性糖链的方法。 即，本发明包括参与除了磷酸甘露糖的糖蛋白的糖链的蛋白质; 的基因编码该蛋白质; 此基因的突变体; 携带突变型基因的载体; 属于毕赤酵母属的酵母菌株已经被转化的由该向量; 用于生产具有减少通过使用转化的酵母菌株的酸性糖链的蛋白质的方法; 和糖蛋白如此产生。
-
公开(公告)号：EP1270570A4
公开(公告)日：2004-02-18
申请号：EP01912460
申请日：2001-03-16
IPC分类号： A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/06 , A61P15/06 , A61P15/10 , A61P15/18 , A61P19/00 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/06 , C07D213/75 , C07D405/12 , C07D409/12 , C07D471/04 , A61K31/437 , A61K31/55 , C07D401/12
CPC分类号： C07D213/75 , C07D405/12 , C07D409/12 , C07D471/04
摘要： Amide compounds represented by the following general formula (I), isomers thereof or pharmaceutically acceptable salts of the same; wherein R1 represents hydrogen etc.; R2 represents hydrogen, etc.; X represents SO¿2?, etc.; Y represents a group of the formula (III), etc.; and a is 2. These compounds exhibit a remarkable and selective Rho kinase inhibitory effect without any troublesome toxicity and are excellent in oral absorbability, pharmacokinetics (drug absorption, distribution, metabolism, excretion, etc.) and physical properties (stability, etc.) as the compounds per se. Owing to these characteristics, these compounds are useful as remedies for various diseases in which Rho kinase participates.
-
公开(公告)号：EP1177796A4
公开(公告)日：2003-11-19
申请号：EP00921077
申请日：2000-04-27
发明人： NAKAMUTA MAKOTO , NAWATA HAJIME , UEHATA MASAYOSHI
IPC分类号： A61K31/16 , A61K31/437 , A61K31/44 , A61K31/4409 , A61P1/16 , A61P29/00 , A61P35/00 , C07D213/75 , C07D471/04 , A61K45/00 , A61K31/27 , A61K31/415 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445
CPC分类号： C07D471/04 , A61K31/16 , A61K31/437 , A61K31/44 , A61K31/4409 , C07D213/75
摘要： Preventives/remedies for liver diseases which contain compounds having an Rho kinase inhibitory activity; and liver astrocyte activation inhibitors. Because of having excellent effects of inhibiting the activation of liver astrocytes, preventing the fibrosis of liver tissues, etc., compounds having an Rho kinase inhibitory activity (for example, (+)- trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl) cyclohexane) are useful in preventing and treating various liver diseases such as hepatitis, hepatic fibrosis, liver cirrhosis and liver cancer.
-
公开(公告)号：EP1004673A4
公开(公告)日：2003-01-15
申请号：EP98911202
申请日：1998-04-03
发明人： OHDA TOYOO , OHYA TOMOSHI , KUWAE SHINOBU , OHYAMA MASAO , KOBAYASHI KAORU , UEMURA YAHIRO
摘要： A process for producing foreign proteins characterized by culturing foreign protein-producing hosts constructed by gene manipulation in media containing fatty acids or salts thereof and surfactants and harvesting the foreign proteins from the cultures. Thus the yields of the foreign proteins produced by the hosts can be elevated. Moreover, the degradation of the foreign proteins by enzymes originating in the hosts can be thus inhibited, which enables mass production of the foreign proteins.
-
公开(公告)号：EP1025847A4
公开(公告)日：2003-01-08
申请号：EP98940584
申请日：1998-08-26
IPC分类号： C07D401/12 , A61K31/50 , A61P9/00
CPC分类号： C07D401/12
摘要： Neovascularization promoters and neovascularization potentiators, containing as the active ingredient pyridazinone compounds represented by general formula (I) or pharmacologically acceptable salts thereof wherein each symbol is as defined in the specification. The pyridazinone compounds of formula (I) and pharmacologically acceptable salts thereof have the effects of promoting neovascularization and potentiating the drugs having these effects, which makes them useful as neovascularization promoters and neovascularization potentiators.
-
公开(公告)号：EP0812588A4
公开(公告)日：2002-11-06
申请号：EP96942623
申请日：1996-12-24
发明人： FUJII TSUNEO , MISHINA TADASHI , TESHIMA KOJI , IMAYOSHI TOMONORI
IPC分类号： A61K31/135 , A61K9/02 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/12 , A61K31/137 , A61P37/06 , A61P37/08
CPC分类号： A61K31/137 , Y10S514/885 , Y10S514/886 , Y10S514/912 , Y10S514/946 , Y10S514/947 , Y10S514/966 , Y10S514/969
摘要： An external preparation for topical administration which aims at inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or pharmaceutically acceptable acid-addition salts thereof.
-
公开(公告)号：EP0885883A4
公开(公告)日：2002-10-16
申请号：EP97903647
申请日：1997-03-03
发明人： TANAKA HIROSHI , KUROITA TAKANOBU , TOGO YOSHIFUMI , ISHIBUCHI SEIGO , FUJIO MASAKAZU , FUTAMURA TAKASHI
IPC分类号： C07D209/14 , C07D231/54 , C07D231/56 , C07D261/20 , C07D401/04 , C07D401/06 , C07D413/06 , C07D471/04 , C07D487/04 , C07D491/052 , C07D495/04 , C07D498/04 , C07D513/04 , C07D401/12 , C07D405/14 , C07D413/14
CPC分类号： C07D413/06 , C07D209/14 , C07D231/54 , C07D231/56 , C07D261/20 , C07D401/04 , C07D401/06 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Fused heterocyclic compounds represented by general formula (I), wherein each symbol is as defined in the description, optical isomers thereof, or pharmaceutically acceptable salts thereof; pharmaceutical compositions containing the compounds of formula (I), the optical isomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable additives; and medicines containing the compounds of formula (I), the optical isomers thereof, or the pharmaceutically acceptable salts thereof. These compounds are useful antipsychotic agents efficacious against not only positive symptoms centering on the hallucination, delusion and the like peculiar to the acute stage of schizophrenia, but also negative symptoms such as emotional torpidity, abulia and autism. They are also expected as highly safe antipsychotic agents reduced in the side effects, such as extrapyramidal symptoms or abnormal internal secretion, observed in the case of administration of conventional antipsychotic agents having D2 receptor blocking effects. Thus these compounds can be used as remedies for diseases including schizophrenia.
-
-
-
-
-
-
-
-
-
搜索结果
80 条记录 (耗时 0.015 秒)
